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 CHAPTER I 
 
INTRODUCTION 
 
Need for Point-of-Care Viral Detection 
An accurate diagnosis is critical for quickly implementing an effective 
response to an invasive pathogen.  There is a need for a fast and reliable 
detection method which can discriminate among a wide variety of pathological 
agents.  There are several effective antiviral medications but their effects are 
acute and it is extremely critical for the efficacy of the antiviral to be administered 
in the early stages of infection, therefore rapid and early diagnosis of a virus 
could lead to better treatment.  The primary use for point-of-care viral detection is 
the selection of pathogen-specific treatments, but correct identification of specific 
pathogen(s) can also help minimize the spread of infection and lead to more 
effective monitoring of long-term complications.   
Another important use for rapid virus detection in particular is in the control 
of over-prescription of antibiotics.  Viral infections are one of the most common 
reasons patients seek medical care, but the misdiagnosis of viral pathogens as 
bacterial has led to the over-prescription of antibiotics (McGowan and Tenover, 
1997).  Two major complications can arise from this misdiagnosis.  First, the 
virus is not effectively treated because antibiotics have no effect on a virus.  
Secondly, treatment with unnecessary antibiotics exacerbates the ever growing 
list of antibiotic resistance pathogens.  Thus point-of-care detection methods 
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which are inexpensive, simple, reliable, and sensitive would have a great impact 
on patient care. 
 In the following pages, traditional and genome-based viral detection 
methods are reviewed.  Pitfalls and limitations of these methods are highlighted.  
In addition to these topics, the extraction of nucleic acids from patient samples in 
both a laboratory and in a clinical setting is discussed.  
 
Traditional Virus Detection Methods 
 Currently there are several viral detection methods available.  
Conventional methods include the current gold standard using cell culture 
methods.  Additional methods include serology and antigen detection and 
diagnostic methods which include immunofluorescence (IF), and enzyme-linked 
immunosorbent assay (ELISA). 
 
Cell Culture 
Cell culture is considered the gold standard for the detection of most 
viruses, principally because it can provide characterization and identification of a 
viable viral pathogen.  It is performed by replicating or amplifying the viral 
pathogen in a suitable host system.  Host systems include laboratory animals or 
an incubated egg but it is most often a culture of cells.  Although it is both 
sensitive and specific, the procedure is expensive, labor intensive, requires a 
high level of expertise, and the results could take days to weeks.  For example, 
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one study showed the diagnosis of a clinical sample for respiratory syncytial virus 
(RSV) by cell culture took up 16 days (Ahluwalia et al., 1987).           
 
Serology 
 This method relies on the body’s immune response to invasion by a 
foreign body.  Serology characterizes the antibodies circulating in the blood.  
Antibody response varies, but typically beginning at the onset of an infection 
there is a rise in antibody titer which continues until the infection has cleared.  
There several serology techniques including ELISA, latex agglutination, 
precipitation, complement-fixation and immunofluorescence.  The technique 
implemented is dependent upon the antibody to be detected.  Serology is often 
used when other methods of virus detection are not possible or when too much 
viral shedding has occurred.  The specificity and sensitivity varies according to 
the technique used.  Disadvantages of serology include poor correlation with 
disease, high background titers, and cross-reactivity.  Serology was also shown 
to have limited diagnostic value when testing for RSV in children younger than 6 
months (Brandenburg et al., 1997).                   
 
Immunofluorescence 
 Immunofluorescence (IF) allows for direct fluorescent antigen labeling or 
indirect visualization of viral antigens by the use of fluorescently labeled 
monoclonal or antispecies antibodies.  This technique is relatively rapid and 
generates results in as little as 1-2 hours (Madeley and Peiris, 2002).  IF is most 
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commonly used to test nasopharyngeal aspirate specimens for respiratory viral 
infections such as respiratory syncytial virus (RSV), parainfluenza viruses, 
influenza A and B and adenovirus.  In order to analyze and obtain useable 
results from the specimen, there must be an adequate number of cells and the 
specimen must be of high-quality.  Therefore, IF requires highly skilled personnel 
to work.  Low sensitivity also remain a major issue with IF.  The method showed 
a detection of only 19% for respiratory viruses when the viral load was below 106 
copies per mL (Kuyper et al., 2006).            
 
Enzyme- Linked Immunosorbent Assay  
 Another common viral detection method that utilizes antibodies is enzyme-
linked immunosorbent assay (ELISA).  There are several different types of ELISA 
including indirect ELISA, sandwich ELISA, and competitive ELISA.  A typical 
ELISA begins by the passive absorption of a monoclonal or polyclonal capture 
antibody to the surface of a well in a microtiter plate, typically a 96-well plate.  A 
solution containing the antigen is then added to each well of the microtiter plate, 
followed by several washing and blocking steps.  A detection molecule is then 
added to each well, this molecule is often a monoclonal enzyme-linked antibody 
that is different than the capture antibody.  If the target virus is present an 
antibody sandwich is formed and any uncoupled antibody is removed in a rinse 
step.  Finally, the enzyme substrate is added which is converted by the enzyme 
linked to the detection antibody to elicit a chromogenic, fluorogenic, or 
electrochemical signal.  ELISA-based systems are often used for point-of-care 
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detection of RSV, influenza, and herpes simplex virus.  However there are major 
drawbacks.  For example, the monoclonal antibodies must be matched pairs 
otherwise they may hinder the binding onto the antigen, the conjugation of the 
enzyme to the antibody limits restricts the amplification and therefore limits the 
sensitivity of the assay, and the enzyme itself can reduce the immunoreactivity of 
the antibody.  Other limitations of antigen detection include false positives, long 
term antigen shedding, and narrow detection window.  ELISA has also been 
shown to have lower sensitivity but higher specificity than IF (Takimoto et al., 
1991).                     
 
Limitations of Traditional Virus Detection Methods 
Despite the wide use of traditional virus detection methods, they still have 
significant limitations.  Although cell culture produces conclusive and 
unambiguous results it requires days to perform.  While serology, IF, and ELISA 
may be faster to perform they are much lower in sensitivity and specificity.  Also 
a major pitfall of any antibody-based detection method is the inability to detect 
virus infection at an early stage. 
 
Genome-Based Virus Detection Methods 
An alternative to antibody-based detection is genome-based methods.  
Genome-based virus detection methods can potentially take full advantage of the 
ever expanding knowledge of viral genomics.  These methods such as 
polymerase chain reaction (PCR), ligase chain reaction (LCR), molecular 
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beacons and DNA microarrays offer potential advantages over traditional 
methods.  The presence and viability of a pathogen can be addressed without 
the need for culturing the organism, the tests are less time consuming so they 
report results faster, and it offers much higher sensitivity over antibody-based 
detection methods.  Genomic detection also can potentially more fully 
characterize a viral infection by identifying the subtype, genotype, variants, 
mutants, and genotypic resistance patterns.     
 
Polymerase Chain Reaction  
 There are three broad classifications of nucleic acid amplification methods 
and these include target amplification, probe amplification and signal 
amplification (Whelen and Persing, 1996).  Polymerase Chain Reaction (PCR) is 
a widely used clinical tool for target amplification.  It can be used for the direct 
detection of pathogen-specific DNA.  It is an extremely sensitive tool which can 
be used to detect molecules with a copy number as low as 1 molecule per 
milliliter, but typically detection is within the range of 10 to 100 molecules per 
milliliter (Palmer et al, 2003).  Reverse transcriptase can be added to the reaction 
to convert RNA to DNA, thus allowing for the use of PCR as an effective tool for 
the detection of viral RNA.  Also multiplex PCR assays allow for the testing of 
multiple viral pathogens simultaneously (Létant et at., 2007).   
The PCR process can be complex, for instance, primer design is a critical 
component for effectively amplifying the target region.  Primers are designed to 
flank the gene of interest and software is available to help with this process.  The 
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process starts by annealing the DNA to separate the strands to allow for binding 
of the primers.  Then in the presence of activated enzyme such as Taq 
polymerase and excess nucleotide bases, amplification of the target DNA then 
occurs through the repeated heating and cooling cycles (Saiki et al., 1988).  In 
traditional PCR, an agarose or polyacrylamide gel electrophoresis combined with 
a dye or fluorescent marker that binds to double-stranded DNA is used to detect 
the final PCR product.  Real time PCR allows for quantitative analysis of the final 
product by the measuring the increasing fluorescence during the PCR process of 
an intercalating dye added to the initial PRC mix, which binds to double-stranded 
DNA (Bustin, 2004).   
 Although there are many attractive features of PCR, it also has a number 
of disadvantages.  The highly sensitive nature of PCR creates an elevated risk of 
contamination, environmental contaminates or contamination from a previous 
sample which can easily introduce variation into PCR results.  The presence of 
DNase or RNase can destroy the target of interest and can also skew PCR 
results.  Therefore, to avoid these potential issues, PCR should be performed by 
a skilled technician in isolated areas which are specifically dedicated to PCR 
preparation.  PCR also requires a large investment in equipment which makes it 
extremely costly to perform.  PCR is extremely useful in research settings but it is 
less useful for point-of-care detection.          
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Ligase Chain Reaction 
 Ligase Chain Reactions (LCR), similar to PCR, is another technique to 
detect and amplify a target sequence.  However unlike PCR, which amplifies the 
target DNA, LCR instead amplifies the probe.  It is described as an 
oligonucleotide probe-based assay.  In this approach ligation of two sets of 
oligonucleotide pairs is triggered by hybridization to the target DNA (Widemann 
et al., 1994).  The probes are designed to so that the junction between the 3’ end 
of upstream and downstream primers coincides with the nucleotide that 
distinguishes one type of target from another.  A positive reaction occurs only 
when the appropriate target is present and is indicated by the ligation of the two 
sets of oligonucleotides.  If the target sequence matches the two adjacent 
oligonucleotides the ligated probes serve as templates and lead to a 2-fold 
amplification in the number of templates.  This is similar to, but less robust than 
the cycling process of PCR.  However, if there is a mismatch at the pair junction 
there is no ligation between the probes, and the oligonucleotides must be ligated 
in order to be detected.  A single base-pair mismatch can prevent ligation of the 
oligonucleotides, making LCR highly sensitivity for detecting single base-pair 
changes or mutations.  LCR has been shown to be as sensitivity as PCR for the 
detection of viruses (Marshall et al., 1994).  Detection strategies for LCR include 
gel electrophoresis or coupling with PCR.    
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 Molecular Beacons 
 Molecular beacons are single-stranded oligonucleotide probes used for 
the detection of specific nucleic acids.  They have been designed to take 
advantage of the stem-and-loop structure of single-stranded oligonucleotides.  
The probe is located in the loop region, and is designed to be complementary to 
the target DNA.  The loop sequence is flanked by a sequence containing a 
fluorophore on one end and a sequence containing a quencher on the other.  
The two flanking regions anneal to form the stem portion of the beacon, and this 
quenches the fluorphore.  However, in presence of target DNA the beacon forms 
a more stable structure by the hybridization of the target to the probe region, this 
opens up the beacon and separates the fluorophore from the quencher thus 
allowing the fluorophore to fluoresce (Tyagi and Kramer, 1996).                 
Molecular beacons can be used in conjunction with PCR, however there 
are uses for molecular beacons independent of PCR.  For example, viral RNA 
detection has been performed using 100 µm gold-clad filaments with covalently 
attached molecular beacons (Perez, Haselton, and Wright, 2009).  The DNA 
probe used was specifically designed to target an RSV gene end-intergenic start 
sequence, and due to the presence of multiple copies of this region it creates 
multiple targets for each strand of RNA.  The DNA functionalized filament was 
then placed in a series of microcapillary tubes containing 200 µL solutions.  The 
first tube contained viral RNA and was followed by wash solutions.  The analysis 
was done measuring the fluorescence of the filament using a flatbed microarray 
scanner.     
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DNA Microarrays 
 PCR, LCR, and molecular probes methods all require either specifically 
identified primers or probes to operate, meaning they all require a priori 
knowledge of the identity of the virus being tested.  DNA microarrays offer a 
diagnostic system which allows for screening samples without such specific a 
priori knowledge and they offer high levels of sensitivity, specificity, automation, 
and throughput capacity, all with reduced sample volume (Ivnitski et al., 2003).   
There are several techniques used to design DNA microarrays.  Generally 
a glass or silicone chip is used to covalently bond hundreds of oligonucleotides 
designed from various viral genomes.  For example, one approach allowed for 
the potential screening of hundreds of viruses simultaneously by utilizing 70-mer 
long oligonucleotides designed from over 140 sequence viral genomes (Wang et 
al., 2002).  Hybridization of the target DNA to the oligonucleotide probes is then 
detected using fluorphores.  Since the specific viral genome location on the 
microarray is known, the identity of the virus can be determined.          
 
Major Roadblock of Genome-Based Virus Detection Methods  
The complexity and reproducibility of the extraction of nucleic acids from 
patient samples remains one of the greatest limitations to genome-based virus 
detection methods.  Patient samples such as blood, urine, stool, cerebrospinal 
fluid, throat swabs, nasal washes, and nasal swabs contain contaminates which 
block the effectiveness of genomic detection methods.  For instance, it has been 
shown that high concentrations of carbohydrates present in clinical samples can 
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inhibit the results of PCR (Monteiro et al., 1997).  Also one of the biggest barriers 
for the implementation of microarrays in clinical settings is the complexity of the 
sample pretreatment and need for a method which is coupled and codependent 
in terms of sample volume, time, and reagent consumption (Lichtenberg, Rooij, 
and Verpoorte, 2002).  In addition to containing contaminants which inhibit 
genome-based detection, patient samples can also contain DNases and RNases, 
which over time, reduces the number of any target viral nucleic acids present in 
the samples.    
There are several ways to approach the issue of handling contaminants in 
patient samples.  One strategy is to identify and remove the contaminant, but this 
method would not be efficient considering that patient samples most likely 
contain several contaminants and the identification and extraction of each would 
be difficult and time consuming.  Another strategy adds a substance to the 
patient sample to remove the contaminant, but this only works if the contaminant 
could either be cleaved or absorbed and if the substance being added does not 
interfere with testing.  A third option is to extract target viral DNA or RNA from the 
patient sample and place it in a contaminant-free buffer.  Although this is a time-
consuming and labor intensive process, this is currently the strategy pursued by 
most laboratories.                          
 
Commercially Available RNA Extraction Kits/Reagents 
There are numerous commercially available methods used specifically to 
isolate RNA from animal cells and tissue samples.  The most popular of these 
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are the Invitrogen Dynabead mRNA Direct kit, Invitrogen TRIzol, the Qiagen 
RNeasy Mini kit, and the Qiagen MagAttract RNA Cell Mini M48 kit.  Each of 
these is briefly described below.       
 
Invitrogen Dynabeads mRNA Direct Kit 
 The Invitrogen Dynabead kit (Oslo, Norway) is designed to isolate mRNA 
from crude lysates of cells and tissue.  It utilizes magnetic beads with a 
covalently bound short sequence of oligo-dT on the surface, and relies on the 
hybridization of the polyA tail of mRNA to the bead-bound oligo-dT for extraction.  
The lysate is mixed with the provided lysis/binding buffer and then added to the 
dynabeads.  Then the beads are washed with a series of wash buffers, also 
provided in the kit.  And finally the isolated mRNA is extracted from the beads 
using the elution buffer.  
 
Invitrogen TRIzol 
TRIzol (Invitrogen, Oslo, Norway) is a monophasic solution of phenol and 
guanidine thiocyanate used for isolating total RNA, DNA and proteins from cell 
and tissue samples.  TRIzol disrupts cells and cellular components without 
disrupting the integrity of the nucleic acids (Simms, Cizdziel, and Chomczynski, 
1993).  The lysate and TRIzol after centrifugation and the addition of chloroform 
separates into an aqueous phase, which contains the RNA, and an organic 
phase, which contains DNA and proteins.  Isopropanol is used to precipitate the 
RNA and ethanol is used to precipitate DNA.  Although it is an effective reagent 
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for isolating, phenol interferes with PCR amplification and therefore necessitates 
removal of the phenol.  Another disadvantage of using TRIzol is that it contains 
toxic substances such as phenol and chloroform.     
 
Qiagen RNeasy Mini Kit  
 The Qiagen RNeasy Mini kit (Germantown, MD), which is based on silica-
membrane technology, is designed for the purification of total RNA from cells and 
tissues.  The sample with lysis buffer is added to the RNeasy Mini spin column, 
which contains a silica-membrane that binds RNA.  Spin or vacuum technology 
paired with wash buffers are then used to eliminate contaminants.  The purified 
RNA is extracted from the membrane in a final elution step.  This procedure is 
very rapid, in fact, a purification can be obtained in a matter of minutes which is 
ideal for a clinical setting. However, it still requires the use of lab equipment such 
as a centrifuge or a vacuum pump which are not typically available in a 
physician’s office.  
 
Qiagen MagAttract RNA Cell Mini M48 Kit 
 Similar to the RNeasy Mini Kit, the Qiagen MagAttract RNA Cell Mini M48 
kit (Germantown, MD) is intended for the purification of total RNA from cells.  
Silica coated magnetic beads are used to bind nucleic acid contained in cell 
lysates.  Then, similar to the Invitrogen Dynabeads kit, the beads are treated with 
a series of wash buffers to eliminate contaminates.  Then finally the RNA is 
eluted from the silica beads with an elution buffer.  One of the major drawbacks 
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of using the MagAttract RNA M48 kit is that it is intended to be used in 
conjunction the Qiagen BioRobot M48 workstation.  It can be used without the 
assistance of the BioRobot, but the manual instructions are not optimized for this.      
 
Ideal Purification for Patient Samples in a Clinical Setting 
The best extraction technique would be simple, safe, fast, cheap, and 
effective.  It needs to be simple so that it does not require the use of a skilled 
technician in order to get the desired results.  Since it will be used within a clinical 
setting it should not be hazardous.  Time is an important factor and the 
preparation of a patient sample should not take longer to perform than the 
detection analysis.  Integration of the extraction strategy into a point-of-care 
device would be difficult if the process was costly therefore it is important that it 
remains inexpensive.  Most important the method needs to isolate enough target 
to run the desired virus detection test.       
An ideal viral detection device allows for the patient sample to be prepared 
and analyzed in a clinical setting, giving accurate and reliable results in short 
amount of time, without requiring the use of skilled technicians, and without 
requiring the need for expensive laboratory equipment.  No existing kit or reagent 
fulfills all of the requirements.  For example, TRIzol may be a simple and cheap 
technique but the trade-off is toxicity, because it requires the handling of 
potentially hazardous chemicals.  Of the kits listed, the RNeasy Mini kit is the 
fastest extraction however, it requires the use of a centrifuge or vacuum which 
increases both the complexity and cost of using this kit for extractions.  The 
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magnetic separation techniques such as Dynabead and MagAttract kits, offer 
certain advantages over the other standard separation procedures.  Magnetic 
separation can be extremely cost effective because of the possible recovery and 
reuse of the magnetic particles (Safarik and Safarikova, 2004).  The 
disadvantage of using the Dynabead or MagAttract kits are that they require 
precise pipetting and handling of several solutions, making them less attractive 
for clinical use.  The kits listed are designed to be used by skilled lab technicians, 
and although they may be the quickest and simplest method for performing 
extraction of genomic target from patient samples in a laboratory, they are not 
the best method for performing extractions in a clinical setting.                 
 
Components of Proposed Magnetic Pull-through Capillary RNA Extraction 
 The goal of this thesis is to design a simple extraction method that is more 
appropriate for use in a clinical setting.  The proposed RNA extraction method 
uses a modified magnetic separation technique to perform the extraction.  The 
components of this proposed method are sketched in Figure 1.  The basic idea of 
this approach combines magnetic entrapment of silica-coated beads and surface 
tension confinement of processing solutions.  In this approach, the sample is 
combined with a lysis buffer and mixed with silica-coated magnetic beads.  Six 
sequential capillary chambers aligned horizontally, with air spacers in between 
each capillary.  The first capillary chamber is initially empty while the other five 
chambers are pre-loaded with processing solutions.  The sample mixed with the 
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Figure 1. Capillary chambers were arranged sequentially on a horizontal stage.  Sample 
lysate with lysis buffer and magnetic beads are added to the first chamber.  As a magnet is 
moved over the exterior of the capillaries the magnetic beads are pulled through the 
chambers and transferred to chamber 6.  This process washes, rinses and elutes RNA from 
the sample lysate.   
lysis buffer and beads is loaded into the empty first chamber.  The 2nd, 3rd, and 
4th chambers are filled with wash buffers.  The 5th chamber is filled with a rinse  
buffer, and the final chamber is filled with an elution buffer.  After the sample is 
added to the first chamber a magnet is placed on the outside of the capillary 
tube.  The beads are attracted to the magnet, and as the magnet is pulled down 
over the wash capillaries, then over the rinse capillary, and then finally over the 
elution capillary the beads follow the magnet.  Because of the small capillary 
diameter (~2mm) the processing solutions do not follow the magnetic beads.  
The spacers between each capillary allow for movement of the beads without 
removal of the buffer from the capillary chamber because the solutions are held 
in place by surface tension.  Figure 2 shows the movement of the beads across a 
spacer.  This allows for sufficient washing of contaminants from the beads and  
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 Figure 2. The beads follow the magnet as the magnet is moved from left to right.  Blue 
represents the processing solutions and the air spacers between them allow for movement of 
the beads from one capillary to the next without transferring solutions.  The retention of the 
solution is due to surface tension holding the solution within the capillary chamber.  
 
for the extraction of viral RNA present in the patient sample.  This method does 
not require a skilled technician to perform it and it does not require any additional 
equipment such as a centrifuge.  It only requires a magnet.  This method also 
does not require pipetting or handling of hazardous chemicals.  Finally, the time 
required to perform this extraction is minimal since it basically removes all liquid 
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handling steps.  The design has the potential to dramatically improve viral RNA 
extractions from patient samples in a clinical setting.                 
 
Overall Study Design 
The next section provides additional details of the proposed magnetic pull-
though capillary RNA extraction method and compares its performance to three 
commercially available extraction kits: Invitrogen Dynabead mRNA Direct kit, the 
Qiagen RNeasy Mini kit, and the Qiagen MagAttract RNA Cell Mini M48 kit.  
Each kit is used to extract viral RNA from patient samples known to contain 
respiratory syncytial virus (RSV).    
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 CHAPTER II 
 
 
 
DEVELOPMENT OF A NOVEL VIRAL RNA EXTRACTION METHOD 
 
Abstract 
The complexity and reproducibility of the extraction of nucleic acids from 
patient samples remains one of the greatest limitations to genome-based virus 
detection methods.  This report describes magnetic pull-through capillary RNA 
extraction method which uses a magnetic to pull magnetic silica beads through a 
series of capillary chambers separated by air spacers to isolate RNA from clinical 
samples.  The pull-through method and the extraction obtained from this 
approach is compared to three commercially available RNA extraction kits: 
Qiagen RNeasy Mini Kit, Qiagen MagAttract RNA Cell Mini M48 kit, Invitrogen 
Dynabeads mRNA Direct kit.  RT-PCR was used to calculate cycle threshold and 
the number of RNA copies per µL.  Clinical samples known to be positive for 
RSV had a copy number of 3 copies per µL for raw sample, 4,577 copies per µL 
for extractions performed using RNeasy kit, µL 755 copies per µL for extractions 
performed using Dynabeads kit, 973 copies per µL for extractions performed 
using MagAttract kit, and 531 copies per µL for extractions performed using the 
magnetic pull-through capillary method..  The proposed magnetic pull-through 
capillary method is simpler, less time consuming, and requires less additional 
equipment than most commercially available RNA extraction kits. This platform 
may prove attractive for point-of-care settings.   
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Introduction 
 
An accurate diagnosis is critical for quickly implementing an effective 
response to an invasive pathogen.  There is a need for a fast and reliable 
detection method which can discriminate among a wide variety of pathological 
agents.  There are several effective antiviral medications but their effects are 
acute and it is extremely critical for the efficacy of the antiviral to be administered 
in the early stages of infection, therefore rapid and early diagnosis of a virus 
could lead to better treatment.  The primary use for point-of-care viral detection is 
the selection of pathogen-specific treatments, but correct identification of specific 
pathogen(s) can also help minimize the spread of infection and lead to more 
effective monitoring of long-term complications.   
Another important use for rapid virus detection in particular is in the control 
of over-prescription of antibiotics.  Viral infections are one of the most common 
reasons patients seek medical care, but the misdiagnosis of viral pathogens as 
bacterial has led to the over-prescription of antibiotics (McGowan and Tenover, 
1997).  Two major complications can arise from this misdiagnosis.  First, the 
virus is not effectively treated because antibiotics have no effect on a virus.  
Secondly, treatment with unnecessary antibiotics exacerbates the ever growing 
list of antibiotic resistance pathogens.  Thus point-of-care detection methods 
which are inexpensive, simple, reliable, and sensitive would have a great impact 
on patient care. 
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 The complexity and reproducibility of the extraction of nucleic acids from 
patient samples remains one of the greatest limitations to genome-based virus 
detection methods.  Patient samples such as blood, urine, stool, cerebrospinal 
fluid, throat swabs, nasal washes, and nasal swabs contain contaminates which 
block the effectiveness of genomic detection methods.  For instance, it has been 
shown that high concentrations of carbohydrates present in clinical samples can 
inhibit the results of PCR (Monteiro et al., 1997).  Also one of the biggest barriers 
for the implementation of microarrays in clinical settings is the complexity of the 
sample pretreatment and need for a method which is coupled and codependent 
in terms of sample volume, time, and reagent consumption (Lichtenberg, Rooij, 
and Verpoorte, 2002).  In addition to containing contaminants which inhibit 
genome-based detection, patient samples can also contain DNases and RNases, 
which over time, reduces the number of any target viral nucleic acids present in 
the samples.    
There are several ways to approach the issue of handling contaminants in 
patient samples.  One strategy is to identify and remove the contaminant, but this 
method would not be efficient considering that patient samples most likely 
contain several contaminants and the identification and extraction of each would 
be difficult and time consuming.  Another strategy adds a substance to the 
patient sample to remove the contaminant, but this only works if the contaminant 
could either be cleaved or absorbed and if the substance being added does not 
interfere with testing.  A third option is to extract target viral DNA or RNA from the 
patient sample and place it in a contaminant-free buffer.  Although this is a time-
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 consuming and labor intensive process, this is currently the strategy pursued by 
most laboratories.  
The best extraction technique would be simple, safe, fast, cheap, and 
effective.  It needs to be simple so that it does not require the use of a skilled 
technician in order to get the desired results.  Since it will be used within a clinical 
setting it should not be hazardous.  Time is an important factor and the 
preparation of a patient sample should not take longer to perform than the 
detection analysis.  Integration of the extraction strategy into a point-of-care 
device would be difficult if the process was costly therefore it is important that it 
remains inexpensive.  Most important the method needs to isolate enough target 
to run the desired virus detection test.       
An ideal viral detection device allows for the patient sample to be prepared 
and analyzed in a clinical setting, giving accurate and reliable results in short 
amount of time, without requiring the use of skilled technicians, and without 
requiring the need for expensive laboratory equipment.  No existing kit or reagent 
fulfills all of these requirements. This paper provides details of a proposed 
magnetic pull-though capillary RNA extraction method and compares its 
performance to three commercially available extraction kits: Invitrogen Dynabead 
mRNA Direct kit, the Qiagen RNeasy Mini kit, and the Qiagen MagAttract RNA 
Cell Mini M48 kit.   
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 Materials and Methods 
 
Clinical Samples 
 Clinical samples were obtained from Dr. John William’s lab (Vanderbilt 
University Hospital, Nashville, TN).  A total 840 de-identified nasal swabs that 
had been placed in opti-MEM media (Invitogen, Oslo, Norway) and frozen at -
80°C were available for this study.  Each sample was previously characterized 
for respiratory syncytial virus (RSV) using RT-PCR.  They were characterized 
after an extraction using Roche Total Nucleic Acid Extraction Kit (Basel, 
Switzerland), and real-time RT-PCR was performed using Roche LC Magna Pure 
machine (Basel, Switzerland).  We obtained samples which tested positive for 
RSV and positive samples were determined to be samples that had a calculated 
cycle threshold (Ct).  We also obtained samples which tested negative for RSV 
and negative samples were determined to be the ones which did not have a 
calculated cycle threshold (Ct) within the cycles that were performed.      
 
Real time RT-PCR 
Rt-PCR was used to estimate the number of viral copies in the test solutions.  
Real time RT-PCR was performed using a Rotor-Gene Q (Qiagen, Germantown, 
MD).  Reactions were done in a 25 μL volume using 0.5μL of either raw clinical 
samples or samples that had RNA extractions performed using various different 
kits, 12.5 μL of 2X One-Step qRT-PCR Buffer plus SYBR (Clontech, Mountain 
View, CA), 0.5 μL of 50X QTaq DNA Polymerase Mix (Clontech, Mountain View, 
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 CA), 0.4μL of 60X qRT Mix (Clontech, Mountain View, CA), 200nM left and right 
RSV primers, and RNase-free water.  The protocol consisted of RT followed by a 
three-step PCR.  RT was performed at 48°C for 20 minutes followed by an initial 
QTaq DNA polymerase activation step of 95°C for 3 minutes and 40 cycles at 
95°C for 15 seconds to denatures, 60°C for 60 seconds to anneal and extend, 
and fluorescence measurements were made after each cycle.  Specificity of the 
amplification was confirmed using melting curve analysis.  Data were collected 
and recorded by [insert software name] and expressed as a function of threshold 
cycle (Ct).  The primer set used was RSV forward primer 5’-
GCTCTTAGCAAAGTCAAGTTGAAATGA-3’ and RSV reverse primer 5’-
TGCTCCGTTGGATGGTGTATT-3’.  The primers were purchased from 
Biosearch Technologies (Novato, CA).  Data was collected and recorded by 
Rotor-Gene Q Software (Qiagen, Germantown, MD) and expressed as a function 
of threshold cycle (Ct) and number of copies of RNA per μL.  Every RT-PCR trial 
was performed with two standard samples from the standard curve, and copy 
number was obtained using a standard curve to relate Ct to starting copy.  Every 
RT-PCR test was performed in triplicate and the results were recorded as an 
average.     
 
PCR Standard Curve for RSV  
 E. coli transformed with the RSV N-gene cloned into pcDNA3.1(-) vectors 
was received from the Crowe Lab (Vanderbilt University, Nashville, TN).  E. coli 
was grown overnight in Miller’s LB Broth (Invitrogen, Oslo, Norway) at 37°C on a 
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 rotating rack.  The next day, growth was confirmed by the turbidity of the broth 
and the plasmid was extracted using a Qiagen Spin Miniprep Kit (Germantown, 
MD).  The concentration of extracted plasmid DNA was then calculated using 
UV-Vis spectroscopy.  The purified plasmid was linearized using Pvu I restriction 
enzymes.  Linearization was confirmed by running both pre- and post-linearized 
plasmids on a 1% agarose gel.  Linearized plasmid was purified using ethanol 
precipitation.  The plasmid was then transcribed into RNA using a T7 
MEGAscript transcription kit (Ambion, Austin, TX).  Appropriate RNA length was 
confirmed on a denaturing agarose-formaldehyde gel.  The N-gene RNA was 
then quantified using UV-Vis spectroscopy.  N-gene RNA was separated into 
aliquots and stored at -80°C.  Ten-fold standard curve dilutions were made in TE 
buffer (Ambion, Austin, TX) ranging from 107 copies per µL to 101 per µL, and 
RT-PCR was performed to create a standard curve comparing the number of 
RNA copies per µL to cycle threshold (Ct).  
 
Comparison of the extraction kits on patient samples 
 RT-PCR was performed on 7 positive and 7 negative clinical samples.  
Comparison were made of the cycle threshold (Ct) and number of copies of RNA 
per µL based on the RT-PCR results performed on patient samples before RNA 
extraction (raw sample) and after RNA extractions using the RNeasy Mini kit 
(Qiagen, Germantown, MD), MagAttract RNA Cell Mini M48 kit (Qiagen, 
Germantown, MD), Dynabeads mRNA Direct kit (Invitrogen, Oslo, Norway), and 
the magnetic pull-though capillary method.       
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RNA Extraction using Magnetic Pull-Through Capillary Method 
 The magnetic pull-though capillary method was used to isolate RNA from 
sample lysates.  Glass capillary chambers were cut from ¼ inch stock tubing into 
80 mm lengths, and the ends were flared outward.  The exterior diameter of the 
chamber is 6mm and the interior diameter of the chambers is 2mm.  Six capillary 
chambers were aligned linearly on the top of a horizontal aluminum stage using 
machined aluminum mounts.  A 1000 μL pipette tip was placed as a spacer in 
between each capillary chamber with the wide end of the pipette tip around the 
preceding capillary chamber and the narrow end sitting the in flared region of the 
next capillary chamber.  The arrangement of the chambers and spacers is 
depicted in Figure 3. The MagAttract RNA Cell Mini M48 kit magnetic beads and 
buffers (Qiagen, Germantown, MD)  were used in conjunction with the magnetic 
pull-though capillary system.  The 1st capillary chamber was initially left empty.  
Chambers 2 to 6 were pre-filled with the processing reagents supplied by 
Qiagen.  The 2nd chamber was filled with 200 μL of MW wash buffer (Qiagen, 
Germantown, MD).  The 3rd and 4th chambers were each with 200 μL of RPE 
wash buffer (Qiagen, Germantown, MD).  The 5th chamber was filled with 200 μL 
of RNase-free water.  The 6th and last chamber was filled with 30 μL RNase-free 
water at 65º C.  Thirty μL of sample lysate was added to 150 μL buffer RLT 
(Qiagen, Germantown, MD) and vortex.  The lysate was then passed though a 
20-gauge needle 5 times.  Twenty μL of the MagAttract bead solution (Qiagen, 
Germantown, MD) was added to the lysate and buffer RLT, the mixture was then 
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 vortexed, and placed on a mixer for 5 minutes at room temperature.  Two 
hundred μL of the lysate, buffer RLT, and MagAttract bead sample was then 
loaded into the first capillary chamber.  A 2.54cm cube of grade 40NdFeB 
magnet (National Imports, Vienna, VA) was placed on top of the first capillary 
chamber then the magnet was slowly pulled at a rate of ~4mm per second 
sequentially along all the spacers and capillary chambers, all the way to the 6th 
and final chamber, the total pull-through time was just under  2 mintues.  Once 
the magnet was on top of the 6th chamber, the elution was collected.  An 
illustration of the movement of the beads across an air spacer is shown in Figure 
4.  The magnet used generates a magnetic field between 100 and 500mT and 
has a magnetic field gradient of 45Tm-1 (Kuhn, Hallahan, and Giorgio, 2006).                            
1                       2                       3               4                        5                       6
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Magnetic beads
 
 
 
Figure 3. Capillary chambers were arranged sequentially on a horizontal stage.  Sample 
lysate with lysis buffer and magnetic beads are added to the first chamber.  As a magnet is 
moved over the exterior of the capillaries the magnetic beads are pulled through the chambers 
and transfers the beads to chamber 6.  This process washes, rinses and elutes RNA from the 
sample lysate.  
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Figure 4. The beads follow the magnet as the magnet is moved from left to right.  The small 
capillary diameter which creates high surface tension and the air spacers allow for movement 
of the beads from one capillary to the next without transferring buffer from one capillary 
chamber to the next.  
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RNA Extraction using RNeasy Mini Kit 
The RNeasy Mini kit (Qiagen, Germantown, MD) was used to isolate RNA 
from sample lysates following the manufacturer’s instructions.  Briefly, 100 μL of 
sample lysate was added to 600 μL buffer RLT (Qiagen, Germantown, MD) and 
then vortexed.  The lysate was then passed though a 20-gauge needle 5 times.  
Then one volume of 70% ethanol was added, then vortexed.  Seven hundred μL 
of the sample was added to the RNeasy spin column (Qiagen, Germantown, 
MD). The spin column was centrifuged at 10,000 rpm for 15 seconds and the 
flow-though was discarded.  Seven hundred μL buffer RW1 (Qiagen, 
Germantown, MD) was added to the spin column, the spin column was 
centrifuged at 10,000 rpm for 15 seconds, and the flow-though was discarded.  
Five hundred μL buffer RPE (Qiagen, Germantown, MD) was added to the spin 
column, centrifuged at 10,000 rpm for 15 seconds, and the flow-though was 
discarded.  Five hundred μL Buffer RPE was added to the spin column, 
centrifuged at 10,000 rpm for 2 minutes, and then the flow-though was discarded.  
For the elution of the RNA from the spin column,50 μL RNase-free water was 
added to the spin column and then centrifuged at 10,000 rpm for 1 minute and 
the flow-though was collected. 
 
RNA Extraction using MagAttract RNA Cell Mini M48 Kit  
The MagAttract RNA Cell Mini M48 kit (Qiagen, Germantown, MD) was 
used to isolate RNA from sample lysates.  The extraction was performed 
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 manually instead of with the assistance of the Qiagen BioRobot M48 workstation 
(Germantown, MD).  One hundred μL of sample lysate was added to 600 μL 
buffer RLT (Qiagen, Germantown, MD) and then vortexed.  The lysate was then 
passed though a 20-gauge needle 5 times.  Sixty μL of the MagAttract bead 
solution (Qiagen, Germantown, MD) was added to the 700 μL of the lysate mixed 
with lysis buffer, vortexed, and then placed on a mixer for 5 minutes at room 
temperature.  The beads were separated on a magnet, supernatant discarded 
and 900 μL of MW wash buffer (Qiagen, Germantown, MD) was added and the 
bead were re-suspended and vortexed.  The beads were separated on a magnet, 
supernatant discarded and 900 μL of RPE wash buffer (Qiagen, Germantown, 
MD) was added and the beads were re-suspended and vortexed, and this was 
repeated once more. The beads were separated on a magnet, supernatant 
discarded and 1 mL RNase-free water was added and pipette 3 times over the 
beads without moving the beads from the magnet.  For elution of the RNA from 
the magnetic beads 50 μL of RNase-free water at 65º C was added, then beads 
were re-suspended and vortexed.  The beads were separated on a magnet and 
the elution was collected.                             
 
RNA Extraction using Dynabeads mRNA Direct Kit 
The Dynabeads mRNA Direct Kit (Invitrogen, Oslo, Norway) was used to 
isolate RNA the sample lysates following the manufacturers instructions.  Briefly, 
100 μL of sample lysate was added to 600 μL buffer RLT and then vortexed.  
The lysate was then passed though a 20-gauge needle 5 times.  Two hundred 
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 and fifty μL Dynabeads (Invitrogen, Oslo, Norway) were placed in 1.5 mL 
eppendorff tube and placed on a magnet, supernatant was removed, and 250 μL 
lysis/binding buffer (Invitrogen, Oslo, Norway) was added.  The beads were 
separated on a magnet, supernatant was removed, 700 μL of the lysate was 
added.  The beads were vortexed and placed on a mixer for 5 minutes at room 
temperature.  The beads were separated on a magnet, supernatant discarded 
and 1 mL of washing buffer A (Invitrogen, Oslo, Norway) was added.  The beads 
were re-suspended and then vortexed.  The beads were separated on a magnet, 
supernatant discarded and 1 mL of washing buffer B (Invitrogen, Oslo, Norway) 
was added and the beads were re-suspended and vortexed., and this was 
repeated once more.  For the removal of the RNA from the beads 50 μL of 10mM 
Tris-HCL elution buffer (Invitrogen, Oslo, Norway) was added, the beads were re-
suspended, vortexed then incubated at 65º C for 2 minutes.  The beads were 
separated on a magnet and the elution was collected.      
      
RNA Extraction kit efficiency test 
Extraction methods were compared under idealized lab conditions.  
Extracted RSV N-gene RNA was diluted in TE buffer (Ambion, Austin, TX) to 105 
copies per µL.  Comparison were made of the threshold cycle (Ct) and number of 
copies of RNA per µL based on the RT-PCR results performed on the RSV N-
gene RNA run without RNA extraction (raw sample) and after RNA extractions 
using the RNeasy Mini kit (Qiagen, Germantown, MD), MagAttract RNA Cell Mini 
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 M48 kit (Qiagen, Germantown, MD), and the magnetic pull-though capillary 
method.      
 
Spiked negative clinical samples 
The RSV N-gene RNA was added to negative nasal swab samples as 
means to control the viral concentration in an environment that otherwise 
resembles a clinical sample.  Three spiked negative clinical samples containing 
105 copies of RNA per µL each were made by adding 20 µL of RSV N-gene RNA 
to 180 µL of a negative clinical sample.  RT-PCR was used to determine the 
cycle threshold (Ct) of spiked samples before and after extraction using RNeasy 
Mini kit.  Comparison were made of the cycle threshold (Ct) and calculated 
number of copies of RNA per µL based on the RT-PCR results performed on the 
spiked negative clinical samples tested without RNA extraction (raw sample) and 
after RNA extractions using the RNeasy Mini kit (Qiagen, Germantown, MD).      
 
Results and Discussion 
 
Comparison of extraction under ideal conditions 
 A comparison of viral RNA extraction from TE buffer found that the 
RNeasy Mini kit was the most efficient with a recovery of 37.8% ± 17.3%, Qiagen 
MagAttract was second with 27.0% ± 4.8%, and the magnetic pull-through was 
the least efficient with a recovery of 11.7% ± 4.8%.  These results are shown in 
Figure 5, the raw data for the threshold cycle can be found in Appendix Table 1, 
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 the raw data for the number of copies can be found in Appendix Table 2, and the 
number of copies normalized to the original can be found in Appendix Table 3.  
The efficiency of the all extraction methods including the commercial kits was 
lower than expected especially considering that the RNA was being extracted 
from TE buffer and not from a clinical samples containing potential contaminants. 
The lower performance of the MagAttract kit as compared to the RNeasy kit is 
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Figure 5. Comparisons were made of the number of copies of RNA per µL before and after 
extraction from TE buffer.  The percent recovery was calculated by dividing the copy number 
values for each extraction method by the copy number obtained before extraction.  Tests were 
run in triplicate and shown as means ± standard deviation (N=3).
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 not surprising considering that particular kit is designed to work most optimally 
with the use of the Qiagen BioRobot M48 workstation, and since the extraction 
was performed manually it was expected that the extraction would not be as 
effective.  Although the magnetic pull-through capillary method did not perform as 
well as the commercial kits did, the results show that this method extracts a 
significant fraction of viral RNA which is readily detected by RT-PCR.   
 
Extraction from negative clinical samples 
 The number of RSV RNA copies per µL, as measured by RT-PCR, of un-
isolated negative clinical sample spiked with 105 RSV RNA was calculated to be 
11,000 ± 1,500 copies per µL.  The same negative clinical sample spiked with 
RSV RNA and isolated using the RNeasy Mini kit showed a much higher copy 
number of 27,000 ± 7,020 copies per µL.  The cycle threshold data is listed in 
Appendix Table 4 and the copy number data can be found in Appendix Table 5.  
The data was normalized to the original copy number present in the spiked 
negative clinical sample, and this data is listed in Appendix Table 6.  The results 
for the percent recovery of RSV RNA from spiked negative clinical samples are 
shown in Figure 6.  The percent recovery before extraction was 11% ± 1% RSV 
RNA and after extraction was 28% ± 7% RSV RNA.  The lower copy number and 
low percent recovery of the raw sample shows the negative effects which 
contaminants within patient samples have on viral detection methods such as 
RT-PCR.  The over 2-fold increase in copy number and percent recovery after 
extraction confirms that running an extraction is necessary to rid the sample of 
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 contaminants which affect the results of RT-PCR.  The comparison of RSV RNA 
recovery from TE buffer and from spiked negative clinical samples after 
extraction using the RNeasy Mini kit is shown in Figure 7.  There is a higher 
percent recovery when extracting from TE buffer than from a sample which 
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Figure 6. Comparisons were made of the number of copies of RNA per µL before and after 
extraction using RNeasy Mini kit from negative clinical samples spiked with RSV N-gene RNA.  
The percent recovery was calculated by dividing the copy number values for before and after 
extraction by the copy number known to be in the sample.  Tests were run in triplicate and 
copy number was calculated and shown as means ± standard deviation (N=3).  
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Figure 7. Comparison of RSV RNA recovery from TE buffer and from spiked negative clinical 
samples after extraction using the RNeasy Mini kit.  The percent recovery was calculated by 
dividing the copy number values for before and after extraction by the copy number known to 
be in the sample.  Tests were run in triplicate and copy number was calculated and shown as 
means ± standard deviation (N=3).  
 
contains containments, so although extraction is necessary to remove 
containments it does not remove all containments which affect RT-PCR results.           
 
Comparison of the extraction kits on patient samples 
The number of RSV RNA copies per µL, as measured by RT-PCR, of un-
extracted RSV positive clinical samples was calculated to be 3 ± 3 copies per µL.  
The same RSV positive clinical samples after extraction was shown to be 4,400 ± 
10,000 copies per µL for extractions done using RNeasy Mini kit, µL 750 ± 1,300 
copies per µL for extractions done using Dynabeads Direct kit, 940 ± 1,000 
copies per µL for extractions done using MagAttract kit, and 510 ± 800 copies per 
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 µL for extractions done using the magnetic pull-through capillary method.  The 
number of RSV RNA copies per µL, as measured by RT-PCR, of un-isolated 
RSV negative clinical samples was calculated to be 0.1 ± 0.2 copies per µL and 
the same RSV positive clinical samples after running extractions was shown to 
be  0.7 ± 1.8 copies per µL for extractions done using RNeasy Mini kit, µL 0.1 ± 
0.2 copies per µL for extractions done using Dynabeads Direct kit,  0.1 ± 0.4 
copies per µL for extractions done using MagAttract kit, and 1.0 ± 1.8 copies per 
µL for extractions done using the magnetic pull-through capillary method.  These 
results are shown in Figure 8.  The data for RSV positive clinical sample cycle 
threshold is in Appendix Table 7, data for RSV negative clinical sample cycle 
threshold is in Appendix Table 8, data for RSV positive clinical sample copy 
number is in Appendix Table 10, data for RSV negative clinical sample copy 
number is in Appendix Table 11.  There is high variation in the average data for 
each kit tested but this variation is largely due to the variation of the clinical 
samples.  Although there is also variation amongst the extraction methods and to 
show this variation a comparison of the cycle threshold (Ct) of the positive clinical 
samples was made and the samples were ranked in order of lowest value to 
highest.  A listing of the ranking for before and after extraction with the various 
methods is shown in Appendix Table 9.   
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Figure 8. Comparisons were made of the number of copies of RNA per µL before and after 
extraction from positive clinical samples (black bars) and negative clinical samples.  
Extractions were performed on 7 positive and 7 negative clinical samples using RNeasy Mini 
kit, Dynabeads mRNA Direct kit, MagAttract RNA Cell Mini M48 kit, and the magnetic pull-
through capillary method.  Tests were performed in triplicate and results are shown as means 
± standard deviation (N=7).  Note the y log-scale, which tends to mask the high standard 
deviations are greater than they appear. 
The best extraction technique for use in a physician’s office would be 
simple, safe, fast, cheap, and effective.  The data shows the magnetic pull-
though capillary method performs similarly to several frequently used commercial 
kits.  The steps for extraction, time necessary and the equipment needed are 
listed in Appendix Table 12 for the RNeasy kit, Appendix Table 13 for the 
Dynabead kit, Appendix Table 14 for the MagAttract kit, and Appendix Table 15 
 38
 for the magnetic pull-through capillary method.  Comparisons of the kits are 
shown in Appendix Table 16.  The magnetic pull-through capillary methods does 
not require as much sample or buffer volume per extraction.  The magnetic pull-
through capillary method has the fewest steps compared with the commercially 
available kits.  The majority of the time and the extra equipment needed for the 
magnetic pull-through capillary method are used in the disruption and 
homogenization of the clinical sample.  Greater optimization of the disruption and 
homogenization could eliminate most of the time necessary to run the extraction 
and could eliminate the use of a 20-gauge needle and syringe, vortex, and a 
rotating mixer, which would remove most of the extra equipment.  Comparing the 
performance and the steps, time, and equipment needed for performing the 
extraction the magnetic pull-through capillary method would be the best for use in 
a clinical setting.  Although the trade-off is a lower efficiency performance, it is 
the quickest, contains the least number of steps, and requires little additional 
equipment.                             
 
Conclusion 
 In summary, the current magnetic pull-through capillary RNA extraction 
method is useful in the extraction of RNA from clinical samples.  It is simpler, less 
time consuming, and requires less additional equipment. This design has the 
potential to be useful in a clinical setting.  Further optimization of the magnetic 
pull-through capillary RNA extraction method is necessary to improve extraction 
efficiency.            
 39
 APPENDIX 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Threshold cycle (Ct)) based on the RT-PCR results were calculated for three 
samples containing RSV N-gene RNA that were performed without RNA extraction (raw 
sample) and after RNA extractions using the RNeasy Mini kit, MagAttract RNA Cell Mini M48 
kit, and the magnetic pull-though capillary method.  Tests were run in triplicate. 
Efficiency Test of Isolation Methods (Threshold Cycle (Ct))
Sample # Raw RNeasy MagAttract Pull-Through
Sample 1 14.62 17.09 16.37 18.78
Sample 2 14.58 16.11 16.88 17.84
Sample 3 14.58 15.51 16.65 17.37
Average 14.59 16.24 16.63 18.00
Standard Deviation 0.03 0.79 0.25 0.72
Table 2. The number of copies of RSV RNA per µL based on the RT-PCR results were 
calculated for three samples containing RSV N-gene RNA that were performed without RNA 
extraction (raw sample) and after RNA extractions using the RNeasy Mini kit, MagAttract RNA 
Cell Mini M48 kit, and the magnetic pull-though capillary method.  Tests were run in triplicate.  
Efficiency Test of Isolation Methods (RSV RNA Copies per µL)
Sample # Raw RNeasy MagAttract Pull-Through
Sample 1 1000000 200000 320000 66000
Sample 2 1000000 380000 220000 120000
Sample 3 1000000 560000 270000 160000
Average 1000000 380000 270000 115333
Standard Deviation 0 180000 50000 47173
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Table 3. The number of copies of RSV RNA per µL based on the RT-PCR results were 
calculated for three samples containing RSV N-gene RNA that were performed without RNA 
extraction (raw sample) and after RNA extractions using the RNeasy Mini kit, MagAttract RNA 
Cell Mini M48 kit, and the magnetic pull-though capillary method.  The copies numbers for the 
samples after RNA extractions were normalized to the raw sample ran without RNA extraction, 
and the results were averaged.  Tests were run in triplicate.  
Efficiency Test of Isolation Methods (Normalized to Raw/Original)
Sample # Raw RNeasy MagAttract Pull-Through
Sample 1 1 0.20 0.32 0.07
Sample 2 1 0.38 0.22 0.12
Sample 3 1 0.55 0.27 0.16
Normalized Average 1 0.38 0.27 0.12
Normalized Standard Deviation 0 0.17 0.05 0.05
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Threshold cycle (Ct)) based on the RT-PCR results were calculated and averaged for 
three samples containing RSV N-gene RNA that was added to negative nasal swab samples 
as means to control the viral concentration in an environment that otherwise resembles a 
clinical sample. Tests were run in triplicate.  
0.840.38Standard Deviation
30.4733.21Average
31.2933.552-06-048
30.5033.281-06-174
29.6132.801-06-171
RNeasyRawSample ID
Spiked Negative Samples (Cycle Threshold (Ct))
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Table 5. The number of copies of RSV RNA per µL based on the RT-PCR results were 
calculated and averaged for three samples containing RSV N-gene RNA that was added to 
negative nasal swab samples as means to control the viral concentration in an environment 
that otherwise resembles a clinical sample. Tests were run in triplicate.  
Spiked Negative Samples (RSV RNA Copies per µL)
Sample ID Original Raw RNeasy
1-06-171 100000 13000 35000
1-06-174 100000 11000 27000
2-06-048 100000 10000 21000
Average 100000 11333 27667
Standard Deviation 0 1528 7024
 
 
Table 6. The number of copies of RSV RNA per µL based on RT-PCR results for samples 
before and after extraction contain RSV N-gene RNA that was added to negative nasal swab 
clinical samples was normalized to the original copy number placed in the sample. 
Spiked Negative Samples (Normalized to Original)
Sample ID Original Raw RNeasy
1-06-171 1 0.13 0.36
1-06-174 1 0.11 0.27
2-06-048 1 0.10 0.21
Normalized Average 1 0.11 0.28
Normalized Standard Deviation 0 0.01 0.07
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Table 7. Threshold cycle (Ct)) based on the RT-PCR results were calculated and averaged for 
seven RSV positive clinical samples. Tests were run in triplicate.  
RSV Positive Clinical Samples (Cycle Threshold (Ct))
Sample ID William's Lab Raw RNeasy Dynabead MagAttract Pull-Through
1-06-012 21.86 34.09 22.49 27.07 26.73 26.93
1-06-018 23.25 35.78 23.20 21.49 27.59 26.32
1-06-088 22.83 30.78 25.62 32.94 35.66 24.63
2-06-025 19.84 31.14 18.12 22.36 23.06 24.11
2-06-027 23.82 32.33 23.03 27.73 25.62 26.20
1-06-159 20.79 36.54 23.12 28.30 22.03 21.98
1-06-163 23.68 32.98 25.73 26.25 23.16 31.27
Average 22.30 33.38 23.04 26.59 26.26 25.92
Standard deviation 1.52 2.21 2.53 3.85 4.63 2.90
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8. Threshold cycle (Ct)) based on the RT-PCR results were calculated and averaged for 
seven RSV negative clinical samples. Tests were run in triplicate. The – indicates that the 
sample did not come up before the 40th  cycle, therefore no cycle threshold was calculated.  
Virus Negative Samples (Cycle Threshold (Ct))
Sample ID William's Lab Raw RNeasy Dynabead MagAttract Pull-Though
1-06-014 - - - - - -
2-06-010 - 35.12 - - - -
4-06-011 - - 39.19 - - -
1-06-090 - 39.11 36.19 35.04 - 31.84
1-06-097 - - 31.62 36.34 33.81 32.39
4-06-027 - - - - - -
1-06-157 - - - - - -
Average - 37.12 35.67 35.69 33.81 32.11
Standard deviation - 2.82 3.81 0.92 0.00 0.39
 
 
Table 9. Ranking of positive clinical samples based on calculated cycle threshold (Ct) values. 
RSV Positive Clinical Samples Ranking Based on (Cycle Threshold (Ct))
Sample ID William's Lab Raw RNeasy Dynabead MagAttract Pull-Through
1-06-012 3 5 2 4 5 6
1-06-018 5 6 5 1 6 5
1-06-088 4 1 6 7 7 3
2-06-025 1 2 1 2 2 2
2-06-027 7 3 3 5 4 4
1-06-159 2 7 4 6 1 1
1-06-163 6 4 7 3 3 7
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Table 10. The number of copies of RSV RNA per µL based on the RT-PCR results were 
calculated and averaged for seven RSV positive clinical samples. Tests were run in triplicate.  
RSV Positive Samples (RSV RNA Copies per µL)
Sample ID Raw RNeasy Dynabead MagAttract Pull-Through
1-06-012 1 1600 90 110 98
1-06-018 0.3 1000 3100 64 140
1-06-088 8 220 2 850 420
2-06-025 6 26000 1800 2200 590
2-06-027 3 1100 59 220 150
1-06-159 0.2 1100 41 2200 2200
1-06-163 2 210 150 1000 6
Average 2.93 4461 749 949 515
Standard deviation 3.26 10214 1307 1016 807
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 11. The number of copies of RSV RNA per µL based on the RT-PCR results were 
calculated and averaged for seven RSV negative clinical samples. Tests were run in triplicate.  
1.850.470.221.870.20Standard deviation
1.060.180.120.760.08Average
0.000.000.000.000.001-06-157
0.000.000.000.000.004-06-027
3.071.250.255.000.001-06-097
4.370.000.570.280.041-06-090
0.000.000.000.040.004-06-011
0.000.000.000.000.542-06-010
0.000.000.000.000.001-06-014
Pull-ThoughMagAttractDynabeadRNeasyRaw
Virus Negative Clinical Samples (RSV RNA Copies per µL)
 
 
 
 
 
 
Sample ID
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Table 12. List of steps, total time and extra supplies needed to perform an extraction using the 
Qiagen RNeasy Mini kit on a sample prior to performing RT-PCR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Qiagen RNeasy Mini Kit  
Steps Time (s) Extra Supplies needed
Disruption and homogenization
1Add 600uL Buffer RLT to cells 10 Pipet, vortex
2Pass lysate through a 20-gauge needle (5x) 25 Syringe, 20-gauge needle
3Add 1 volume 70% ethanol 10 Pipet
RNA isolation
4Add 700uL sample to RNeasy spin column 10 Pipet, 
5Centrifuge at 10,000rpm 15 Centrifuge
6Discard flow-through 10 Pipet
7Add 700uL Buffer RW1 10 Pipet, vortex
8Centrifuge at 10,000rpm 15 Centrifuge
9Discard flow-through 10 Pipet
10Add 500uL Buffer RPE 10 Pipet, vortex
11Centrifuge at 10,000rpm 15 Centrifuge
12Discard flow-through 10 Pipet
13Add 500uL Buffer RPE 10 Pipet, vortex
14Centrifuge at 10,000rpm 120 Centrifuge
15Place RNeasy spin column in new collection tube 10
16Add 35-50 uL RNase-free water 10 Pipet, vortex
17Centrifuge at 10,000rpm 60 Centrifuge
Total 360s
6min
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Table 13. List of steps, total time and extra supplies needed to perform an extraction using the 
Invitrogen Dynabeads mRNA Direct kit on a sample prior to performing RT-PCR. 
Invitrogen Dynabeads mRNA Direct Kit
Steps Time (s) Extra Supplies needed
Preparation of Dynabeads Oligo(dT)25
1 Resuspend Dynabeads 60 Vortex
2 Transfer 250uL of beads from stock tube 10 Pipet
3 Place on magnet (when suspension is clear) 30 Magnet
4 Remove supernatant 10 Pipet
5 Remove from magnet 2
6 Add 250ul Lysis/Binding Buffer 10 Pipet, vortex
Preparation of Lysate from Cultured Cells/ Cell Suspensions
7 Add 1250ul Lysis/Binding Buffer to lysate 10 Pipet
8 Pass lysate through a 20-gauge needle (5x) 25 Syringe, 20-gauge needle
9 Centrifuge to reduce foam 10 Centrifuge
Direct mRNA Isolation Protocol
10 Place beads on magnet 30 Magnet
11 Remove Lysis/Binding Buffer from beads 10 Pipet
12 Remove from magnet 2
13 Add sample lysate 10 Pipet, vortex
14 Incubate with continuous mixing at RT 300 Rotating mixer
15 Place on magnet  120 Magnet
16 Remove supernatant 10 Pipet
17 Add 1mL Washing Buffer A 10 Pipet, vortex
18 Place on magnet 30 Magnet
19 Remove supernatant 2 Pipet
20 Add 1mL Washing Buffer A 10 Pipet, vortex
21 Place on magnet 30 Magnet
22 Remove supernatant 2 Pipet 
23 Add 1mL Washing Buffer B 10 Pipet, vortex
24 Place on magnet 30 Magnet
25 Remove supernatant 2 Pipet
26 Add 25uL of 10mM Tris-HCL (Elution Buffer) 10 Pipet, vortex
27 Incubate at 65-80 C 120 Heating block
28 Place on magnet 10 Magnet
29 Remove supernatant 30 Pipet
30 Transfer supernatant to new Rnase-free tube 10 Pipet
Total 955 s
16 min
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Table 14. List of steps, total time and extra supplies needed to perform an extraction using the 
Qiagen MagAttract RNA Cell Mini M48 kit on a sample prior to performing RT-PCR. 
Qiagen MagAttract RNA Cell Mini M48 Kit
Steps Time (s) Extra Supplies needed
Disruption and homogenization
1 Add 720uL Buffer RLT to cells 10 Pipet, vortex
2 Pass lysate through a 20-gauge needle (5x) 25 Syringe, 20-gauge needle
RNA Isolation Protocol (manual, w/o use of BioRobot)
3 Add 60uL bead solution 10 Pipet, vortex
4 Incubate with continuous mixing at RT 300 Rotating mixer
5 Separate on magnet 10 Magnet
6 Discard supernatant 10 Pipet
7 Add 900uL MW Wash Buffer 10 Pipet, vortex
8 Separate on magnet 10 Magnet
9 Discard supernatant 10 Pipet
10 Add 900uL RPE Wash Buffer 10 Pipet, vortex
11 Separate on magnet 10 Magnet
12 Discard supernatant 10 Pipet
13 Add 900uL RPE Wash Buffer 10 Pipet, vortex
14 Separate on magnet 10 Magnet
15 Discard supernatant 10 Pipet
16 Add 1mL H2O, pipet 3x 10 Pipet
17 Discard supernatant 10 Pipet
18 Add 50-200uL RNase free water at 65C 10 Pipet, heat block
19 Separate on magnet 10 Magnet
20 Collect the eluate 10 Pipet
Total 505 s
8 min
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 15. List of steps, total time and extra supplies needed to perform an extraction using the 
magnet pull-through capillary RNA extraction method on a sample prior to performing RT-
PCR. 
Magnet Pull-Through Capillary RNA Extraction Method
Steps Time (s) Extra Supplies needed
Disruption and homogenization
1 Add 150uL Buffer RLT to cells 10 Pipet, vortex
2 Pass lysate through a 20-gauge needle (5x) 25 Syringe, 20-gauge needle
RNA Isolation Protocol (manual, w/o use of BioRobot)
3 Add 30uL bead solution 10 Pipet, vortex
4 Incubate with continuous mixing at RT 300 Rotating mixer
5 Load 200uL of lysate into the first chamber 10 Pipet
6 Load 200uL of MW Wash buffer into the second chamber 10 Pipet
7 Load 200uL of RPE Wash Buffer into the third chamber 10 Pipet
8 Load 200uL of RPE Wash Buffer into the fourth chamber 10 Pipet
9 Load 200uL of RNase-free water into the fifth chamber 10 Pipet
10 Load 30uL of RNase-free water into the sixth chamber 10 Pipet
11 Drag magnet from first to last chamber 60 Magnet
12 Collect the elute 10 Pipet
Total 475s
8min
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Table 16. Comparison of the number of steps, total time and extra supplies needed to perform 
an extraction using the Qiagen RNeasy Mini kit, Invitrogen Dynabeads mRNA Direct kit, 
Qiagen MagAttract RNA Cell Mini M48 kit, and the magnet pull-through capillary RNA 
extraction method on a sample prior to performing RT-PCR. 
Isolation Method Total Time (mins) No. of Steps Extra Instrumentation
Raw sample, no isolation 0 0
Qiagen RNeasy Mini Kit  6 17 Pipet, syringe, 20-gauge needle, vortex, centrifuge
Invitrogen Dynabeads mRNA Direct Kit 16 30 Pipet, syringe, 20-gauge needle, vortex, centrifuge, heating block, rotating mixer, magnet
Qiagen MagAttract RNA Cell Mini M48 Kit 8 20 Pipet, syringe, 20-gauge needle, vortex, heating block, rotating mixer, magnet
Magetic Pull-Through Capillary Method 8 12 Pipet, syringe, 20-gauge needle, vortex, rotating mixer, magnet
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